Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.

For plasma pTau217, post-hoc analysis of the change from baseline with ACI-35.030 treatment, when compared to the corresponding change from baseline for the pooled placebo group, was nominally significant at weeks 31, 36, and 74 for the 900 μg dose and 10, 15, and 36 for the 1800 μg dose ( Fig. 3 and Table 6 ).

also in 7,732 other papers